About Phio Pharmaceuticals Corp
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://phiopharma.com/
Frequently Asked Questions
What is the 52-week range for PHIO?
The 52-week high is $4.1899 and the 52-week low is $0.8127.
What is the P/E ratio for PHIO?
The P/E ratio data is currently unavailable.
What is the dividend yield for PHIO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -87.41%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -3935.71%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.56.
Analyst Recommendation Trends
Wall Street analyst consensus for PHIO over the last few months:
Latest PHIO News
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell CarcinomaKing of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer, today announced that it will present at the Life Sciences Future 2026 Conference, taking place September 30 to October 1, 2026, at the..
Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
Company Proposes Planned Phase 2b Neoadjuvant Study Following Successful Completion of Phase 1b TrialKing of Prussia, Pennsylvania--(Newsfile Corp. - September 14, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that, following the formal completion of the Phase 1b clinical study, it has submitted a meeting request and...
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Management to Meet with Investors and Highlight Progress and Future Development Plans for PH-762King of Prussia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-28 | Plott Ronald Todd | +17,000 | - | - |
| 2026-09-28 | Carson Lisa Cabott | +108,000 | - | - |
| 2026-09-28 | Bitterman Robert J | +400,000 | - | - |
| 2026-09-24 | BRADFORD PATRICIA A | +6,500 | $1.0127 | $6,583 |
| 2026-09-22 | Bitterman Robert J | +2,000 | $1.0289 | $2,058 |
| 2026-09-15 | BRADFORD PATRICIA A | +12,000 | $1.03 | $12,360 |
| 2026-09-11 | Carson Lisa Cabott | -12,888 | $1.03 | $13,275 |
| 2026-09-11 | Bitterman Robert J | -68,550 | $1.03 | $70,607 |
| 2026-08-19 | Plott Ronald Todd | +15,000 | $1.14 | $17,100 |
| 2026-08-18 | Bitterman Robert J | +10,000 | $1.06 | $10,600 |
| 2026-02-05 | Freeman Jonathan E | +16,600 | - | - |
| 2026-02-05 | Deming David H | +23,800 | - | - |
| 2026-02-05 | Carson Lisa Cabott | +47,000 | - | - |
| 2026-02-05 | Lockshin Curtis | +16,600 | - | - |
| 2026-02-05 | BRADFORD PATRICIA A | +18,500 | - | - |
| 2026-02-05 | Bitterman Robert J | +120,000 | - | - |
| 2025-12-31 | Bitterman Robert J | +5,000 | $1.03 | $5,150 |
| 2025-12-23 | Bitterman Robert J | +5,000 | $1.02 | $5,100 |
| 2025-11-21 | Bitterman Robert J | +5,000 | $1.14 | $5,700 |
| 2025-11-18 | Bitterman Robert J | +5,000 | $1.27 | $6,350 |